NeOnc Technologies Holdings, Inc. Common Stock (NTHI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($-17.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NeOnc Technologies Holdings, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NeOnc Technologies Holdings, Inc. Common debt and liabilities for a breakdown of total debt and financial obligations.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rimoni
TA:RIMO
|
0.074x |
|
S.Y.PANEL Co Ltd
KQ:109610
|
-0.087x |
|
Klingelnberg AG
SW:KLIN
|
-0.084x |
|
Hankook Cosmet
KO:123690
|
0.050x |
|
Hillgrove Resources Ltd
AU:HGO
|
0.085x |
|
We & Win Development Co Ltd
TW:2537
|
0.033x |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
0.122x |
|
Cavatina Holding S.A.
WAR:CAV
|
0.003x |
Annual Cash Flow Conversion Efficiency for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see NeOnc Technologies Holdings, Inc. Common market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.51 Million | $-20.36 Million | 1.163x | +51.95% |
| 2024-12-31 | $-5.50 Million | $-4.21 Million | 0.765x | +469.55% |
| 2023-12-31 | $-13.99 Million | $-1.88 Million | 0.134x | -75.99% |
| 2022-12-31 | $-1.58 Million | $-881.74K | 0.560x | +269.14% |
| 2021-12-31 | $-2.62 Million | $-396.69K | 0.152x | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more